X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.reuters.com/business/healthcare-pharmaceuticals/neurocrine-founder-ceo-gorman-retire-october-2024-05-28/
https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-us-fda-approval-ingrezzar
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-ingrezza-valbenazine-capsules-interim-data-demonstrating-sustained-improvements-in-chorea-associated-with-huntingtons-disease-through-week-50-at-huntington-study-group-2023-301969545.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-us-fda-accepts-new-drug-application-for-ingrezza-valbenazine-oral-granules-sprinkle-formulation-301926943.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-data-at-mds-international-congress-of-parkinsons-disease-and-movement-disorders-demonstrating-comparable-improvement-over-time-in-tardive-dyskinesia-severity-and-impact-following-treatment-with-in-301911735.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-ingrezza-valbenazine-capsules-data-demonstrating-early-and-sustained-improvements-in-chorea-associated-with-huntingtons-disease-301910386.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-fda-approval-of-ingrezza-valbenazine-capsules-for-the-treatment-of-chorea-associated-with-huntingtons-disease-301904823.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-ingrezza-valbenazine-capsules-data-on-tardive-dyskinesia-improvement-regardless-of-baseline-antipsychotic-use-at-2023-psych-congress-elevate-301840746.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-full-kinect-hd-phase-3-study-results-of-valbenazine-for-the-treatment-of-chorea-associated-with-huntingtons-disease-in-the-lancet-neurology-301828576.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/lupin-gets-tentative-usfda-approval-to-market-generic-valbenazine-capsules/articleshow/99034337.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-data-on-in-vitro-dissolution-performance-of-ingrezza-valbenazine-capsule-contents-via-soft-foods-or-feeding-tube-at-amda--paltc-2023-annual-conference-301766345.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-data-on-improvements-over-time-with-long-term-use-of-ingrezza-valbenazine-capsules-in-older-and-elderly-patients-at-the-american-association-for-geriatric-psychiatry-2023-annual-meeting-301761782.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-us-fda-accepts-supplemental-new-drug-application-for-valbenazine-as-a-treatment-for-chorea-associated-with-huntington-disease-301709335.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215962
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215984
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-additional-phase-3-data-for-kinect-hd-study-evaluating-valbenazine-for-chorea-associated-with-huntington-disease-at-hsg-2022-301666869.html
https://health.economictimes.indiatimes.com/news/pharma/zydus-gets-tentative-usfda-approval-for-valbenazine-capsules/94914051
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216137
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-ingrezza-valbenazine-data-on-sustained-treatment-response-at-psych-congress-2022-301626507.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-ingrezza-valbenazine-data-on-tardive-dyskinesia-improvement-and-stability-of-psychiatric-symptoms-at-american-psychiatric-association-annual-meeting-2022-301552333.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-positive-phase-3-data-for-kinect-hd-study-evaluating-valbenazine-for-chorea-associated-with-huntington-disease-301439605.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-ingrezza-valbenazine-and-ongentys-opicapone-data-at-the-mds-virtual-congress-2021-301373350.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-data-from-its-movement-disorder-programs-for-tardive-dyskinesia-and-parkinsons-disease-at-upcoming-scientific-meetings-301124175.html
http://www.pmlive.com/pharma_news/tevas_weak_pipeline_hit_by_tourettes_drug_trial_failure_1326565
http://www.pmlive.com/pharma_news/us_backs_sanofis_fast-track_coronavirus_vaccine_1326478
https://www.biopharmadive.com/news/neurocrine-xenon-research-deal-pipeline-epilepsy/568263/
https://www.prnewswire.com/news-releases/neurocrine-biosciences-publishes-long-term-ingrezza-valbenazine-data-in-the-journal-of-clinical-psychopharmacology-demonstrating-once-daily-40-mg-and-80-mg-capsules-reduced-involuntary-movements-in-adults-with-tardive-dyskinesi-300956831.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-analyses-on-ingrezza-valbenazine-and-opicapone-at-the-2019-american-academy-of-neurology-annual-meeting-300841132.html
https://endpts.com/jj-beats-novartis-blockbuster-rival-in-a-head-to-head-showdown-over-the-psoriasis-market/
https://seekingalpha.com/article/4223419-neurocrine-biosciences-smacked-rising-expectations-fraying-nerves
https://www.fiercepharma.com/pharma/as-td-drugs-get-more-play-docs-are-coming-around-to-teva-s-austedo-analyst
https://www.fiercebiotech.com/biotech/after-disappointing-2016-new-drug-approvals-roared-back-to-life-2017
Market Place
Share 
